Bryson D Bennett

US Patent:

6866785, Mar 15, 2005

Filed:

Aug 13, 2001

Appl. No.:

09/929275

Inventors:

Richard N. Zare - Stanford CA, US
Maria T. Dulay - Sunnyvale CA, US
Joselito P. Quirino - Stanford CA, US
Bryson Bennett - Murray UT, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Stanford CA

International Classification:

B01D015/08

US Classification:

210656, 210635, 2101982, 210658, 2101983

Abstract:

A separation column and a method of making the separation column are provided. The separation column includes a separation channel and fritless separation medium in the channel. The separation medium includes a porous matrix, and the porous matrix includes a metal organic polymer, such as a photopolymer. The separation medium can be used to separate a sample of analytes.

US Patent:

6875348, Apr 5, 2005

Filed:

Apr 16, 2002

Appl. No.:

10/124654

Inventors:

Richard N. Zare - Stanford CA, US
Maria T. Dulay - Sunnyvale CA, US
Joselito P. Quirino - Sunnyvale CA, US
Bryson D. Bennett - Murray UT, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Stanford CA

International Classification:

B01D015/08

US Classification:

2101982, 2101983, 210635, 210656, 210658

Abstract:

A separation column and a method of preparing the separation column are provided. The separation column includes a separation channel and a porous matrix in the channel. The porous matrix includes a metal organic polymer, such as a photopolymer. The porous matrix can be a separation medium adapted to separate a sample of analytes or a frit adapted to retain a separation medium in the channel.

US Patent:

6884346, Apr 26, 2005

Filed:

Oct 15, 2001

Appl. No.:

09/978515

Inventors:

Richard N. Zare - Stanford CA, US
Maria T. Dulay - Sunnyvale CA, US
Joselito P. Quirino - Stanford CA, US
Bryson Bennett - Murray UT, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Stanford CA

International Classification:

B01D015/08

US Classification:

2101982, 2101983, 210635, 210656, 210658

Abstract:

A separation column and a method of making the separation column are provided. The separation column includes a separation channel and a separation medium in the channel. The separation medium includes a porous matrix, and the porous matrix includes a support and a stationary phase. The support includes a metal organic polymer, such as a photopolymer, and the stationary phase includes a bonded phase. The separation medium can be used to separate a sample of analytes.

US Patent:

8158677, Apr 17, 2012

Filed:

Jun 2, 2008

Appl. No.:

12/156517

Inventors:

Josh Munger - Rochester NY, US
Bryson Bennett - Metuchen NJ, US
Thomas Shenk - Princeton NJ, US
Joshua Rabinowitz - Princeton NJ, US

Assignee:

The Trustees of Princeton University - Princeton NJ

International Classification:

A61K 31/34
A61K 31/38
A61K 31/35

US Classification:

514473, 514461, 514445, 514438, 514471, 514451, 514460

Abstract:

Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i. e. , to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections.

US Patent:

20050034723, Feb 17, 2005

Filed:

Aug 4, 2004

Appl. No.:

10/912417

Inventors:

Bryson Bennett - Mountain View CA, US
Ron Hale - Woodside CA, US
Amy Lu - Los Altos CA, US
Daniel Myers - Mountain View CA, US
Krishnamohan Sharma - Santa Clara CA, US
Joshua Rabinowitz - Princeton NJ, US

International Classification:

A61M011/00
A61M015/00

US Classification:

128203120

Abstract:

An assembly and method for producing a condensation aerosol are disclosed. The assembly includes a heat-conductive metal substrate with an oxidation resistant exterior surface and a drug composition film on the exterior surface and is for use in an aerosol device. The thickness of the film and the surface of the substrate is such that the aerosol formed by vaporizing and condensing the drug composition the aerosol contain 10% by weight or less drug-degradation products and at least 50% of the total amount of the drug composition in the film. The methods for treating the exterior surface include heat and chemical treatment and formation of a protective overcoat.

US Patent:

20110240014, Oct 6, 2011

Filed:

Apr 1, 2011

Appl. No.:

13/078668

Inventors:

Bryson Bennett - Mountain View CA, US
Ron L. Hale - Woodside CA, US
Amy Lu - Los Altos CA, US
Daniel J. Myers - Mountain View CA, US
Krishnamohan Sharma - Santa Clara CA, US
Joshua D. Rabinowitz - Princeton NJ, US

Assignee:

ALEXZA PHARMACEUTICALS, INC. - Mountain View CA

International Classification:

A61M 11/00

US Classification:

12820014

Abstract:

An assembly and method for producing a condensation aerosol are disclosed. The assembly includes a heat-conductive metal substrate with an oxidation resistant exterior surface and a drug composition film on the exterior surface and is for use in an aerosol device. The thickness of the film and the surface of the substrate is such that the aerosol formed by vaporizing and condensing the drug composition the aerosol contain 10% by weight or less drug-degradation products and at least 50% of the total amount of the drug composition in the film. The methods for treating the exterior surface include heat and chemical treatment and formation of a protective overcoat.

US Patent:

20130065850, Mar 14, 2013

Filed:

Apr 3, 2012

Appl. No.:

13/438616

Inventors:

Josh MUNGER - Rochester NY, US
Bryson BENNETT - Metuchen NJ, US
Thomas SHENK - Princeton NJ, US
Joshua RABINOWITZ - Princeton NJ, US

Assignee:

THE TRUSTEES OF PRINCETON UNIVERSITY - Princeton NJ

International Classification:

A61K 31/7076
A61K 31/395
A61K 31/20
A61K 31/122
A61K 31/135
A61K 31/473
A61K 31/4545
A61K 31/5377
A61K 31/403
A61K 31/44
A61K 31/194
A61K 31/15
A61K 31/53
A61K 31/519
A61K 31/197
A61K 31/4706
A61K 31/09
A61K 31/353
A61K 31/426
A61K 31/501
A61K 31/496
A61K 31/216
A61K 31/192
A61K 31/4178
A61K 31/42
A61K 31/444
A61K 31/4245
A61K 31/428
A61K 31/12
A61K 31/433
A61K 31/661
A61K 31/41
A61K 31/4196
A61K 31/505
A61K 31/6615
A61K 31/4015
A61K 31/366
A61P 31/12
A61P 31/20
A61P 31/14
A61P 31/18
A61P 31/16
A61P 31/22
C12Q 1/70
G01N 27/62
A61K 31/365

US Classification:

514 47, 514449, 514450, 514475, 514473, 514559, 514680, 514641, 514297, 514316, 5142372, 5142358, 514410, 514345, 514574, 514640, 514245, 5142651, 514567, 514313, 514721, 514456, 514369, 51425202, 51425313, 51425203, 514545, 514543, 514568, 514397, 514445, 514378, 514333, 514364, 514367, 514679, 514363, 514119, 514381, 514384, 514275, 514108, 514425, 5142634, 5142335, 514453, 435 5

Abstract:

Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.

US Patent:

20160346309, Dec 1, 2016

Filed:

Dec 21, 2015

Appl. No.:

14/977424

Inventors:

- Princeton NJ, US
Bryson Bennett - Metuchen NJ, US
Thomas Shenk - Princeton NJ, US
Joshua Rabinowitz - Princeton NJ, US

International Classification:

A61K 31/7076
A61K 31/336
A61K 31/341
A61K 31/194
A61K 31/381
A61K 31/53
A61K 31/403
A61K 31/4545
A61K 31/5377
A61K 31/357
A61K 31/15
A61K 31/337
A61K 31/365
A61K 31/122

Abstract:

Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.